Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIxico Regulatory News (IXI)

Share Price Information for Ixico (IXI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 7.00
Bid: 6.75
Ask: 7.25
Change: 0.00 (0.00%)
Spread: 0.50 (7.407%)
Open: 7.00
High: 7.00
Low: 7.00
Prev. Close: 7.00
IXI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Placing and Open Offer

25 Mar 2008 07:17

Phytopharm PLC25 March 2008 25 March 2008 Phytopharm plc Results of Placing and Open Offer On 28 February 2008, Phytopharm plc (PYM: London Stock Exchange) ("Phytopharm"or the "Company") announced a Placing and Open Offer of 38,929,048 New OrdinaryShares at 22p per share to raise approximately £8.6 million (£7.4 million net ofexpenses) in order, together with the Company's existing funds, to furtherdevelop and exploit the potential of the product candidates in its clinicalpipeline. The Placing has been fully underwritten by KBC Peel Hunt. Under the terms of the Placing Agreement, KBC Peel Hunt has conditionally placed22,854,630 Placing Shares with institutional and other investors (subject toclawback to satisfy valid applications by Qualifying Shareholders) at the IssuePrice. Additionally, undertakings to subscribe for 16,074,418 New OrdinaryShares, in aggregate, have been received from Existing Ordinary Shareholders. Qualifying Shareholders were invited to subscribe for Open Offer Shares on thebasis of 7 New Ordinary Shares for every 10 Existing Ordinary Shares held at theRecord Date. Under the Open Offer which closed at 11.00 a.m. on 20 March 2008, validapplications have been received in respect of 22,844,201 shares (representingapproximately 58.68 per cent. of the 38,929,048 Open Offer Shares availableunder the Open Offer). The remaining shares have been placed with institutionalinvestors and with the Directors of Phytopharm in accordance with the Placingarrangements. The Placing and Open Offer remain conditional, inter alia, upon the passing ofcertain resolutions to be proposed at the Company's Extraordinary GeneralMeeting, to be held at 10.30 a.m. on 27 March 2008, being duly passed andadmission of the New Ordinary Shares to trading on the London Stock Exchange andlisting on the Official List of the UK Listing Authority becoming effective. The New Ordinary Shares, when issued and fully paid, will rank pari passu in allrespects with the Existing Ordinary Shares. Subject to the passing of certainresolutions at the Extraordinary General Meeting, admission of the New OrdinaryShares is expected to become effective on 28 March 2008. The definitions used in this announcement shall have the same meanings given tothem in the Prospectus dated 28 February 2008. Notes to Editors Phytopharm plc Phytopharm is a pharmaceutical development and functional food company. Ourproducts are developed from medicinal plants, thereby reducing the developmentrisk, cost and time to market. As a virtual company, Phytopharm's model iscentred on a lean cash burn with all laboratory, manufacturing and clinical workout-sourced to specialists, while core competencies such as strategy andmanagement are maintained in-house. Close collaboration with charitableorganisations enhances our interaction with worldwide specialists andaccelerates our development programmes increasing their value. For furtherinformation about Phytopharm please see our website at www.phytopharm.com Enquiries U.K. Investor Relations KBC Peel Hunt (Sponsor, Phytopharm plc FD Stockbroker and Underwriter) Dr Daryl Rees CEO David Yates Capel Irwin Piers Morgan CFO John Dineen Matt Goode +44 1480 437 697 +44 207 831 3113 +44 207 418 8900 This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
8th Mar 20227:00 amRNSContract worth circa £800k
14th Feb 20227:00 amRNSLaunch of IXIQ.Ai Deep learning AI-based platform
8th Feb 202212:30 pmRNSHolding(s) in Company
8th Feb 20227:00 amRNSContract award worth circa £1.0m
31st Jan 20227:00 amRNSAppointment of Senior Therapeutic Advisor
26th Jan 20227:00 amRNSDementia collaboration
21st Jan 20227:00 amRNSNon-Executive Director Appointment
20th Jan 202210:50 amRNSResult of AGM
20th Jan 20227:00 amRNSHuntington’s disease contract update
10th Jan 20227:00 amRNSGrant of share options
7th Dec 20217:00 amRNSFinancial Results for the year ended 30 Sept 2021
22nd Nov 20217:00 amRNSNotice of Results
1st Nov 20216:08 pmRNSHolding(s) in Company
1st Nov 20217:00 amRNSNew contract worth >£1.0m
20th Oct 20214:27 pmRNSContract update
18th Oct 20217:00 amRNSTrading Update for year ended 30 September 2021
22nd Sep 20217:00 amRNSNew contract worth >$750k
20th Sep 20217:00 amRNSPhase II HD contract with new client worth >$500K
8th Sep 20217:00 amRNSPhase I MSA contract award worth >$500k
6th Aug 20217:00 amRNSTrading Update
23rd Jun 20213:32 pmRNSIssue of Equity
21st Jun 20212:31 pmRNSHolding(s) in Company
15th Jun 20217:00 amRNSFurther investment in Ixico plc
11th Jun 202111:35 amRNSHolding(s) in Company
25th May 20217:00 amRNSHalf yearly report to 31 March 2021
20th May 20217:00 amRNSPhase II Alzheimer’s disease contract award
19th May 20217:00 amRNSContract win for new neuroinflammatory disorder
11th May 20217:00 amRNSNotice of results
28th Apr 20217:00 amRNSContract win for new stroke study
26th Apr 20217:00 amRNSTrading update
19th Apr 20218:21 amRNSHolding(s) in Company
12th Apr 20214:00 pmRNSHolding(s) in Company
12th Apr 20217:00 amRNSInvestment in Ixico plc
1st Apr 20217:00 amRNSHolding(s) in Company
25th Mar 20219:14 amRNSPDMR Transaction
24th Mar 20219:05 amRNSSecond Price Monitoring Extn
24th Mar 20219:00 amRNSPrice Monitoring Extension
23rd Mar 20214:40 pmRNSSecond Price Monitoring Extn
23rd Mar 20214:35 pmRNSPrice Monitoring Extension
23rd Mar 20213:05 pmRNSHuntington’s disease Phase III contract updates
15th Mar 20214:41 pmRNSSecond Price Monitoring Extn
15th Mar 20214:35 pmRNSPrice Monitoring Extension
15th Mar 20212:06 pmRNSSecond Price Monitoring Extn
15th Mar 20212:00 pmRNSPrice Monitoring Extension
15th Mar 202111:06 amRNSSecond Price Monitoring Extn
15th Mar 202111:01 amRNSPrice Monitoring Extension
15th Mar 20217:00 amRNSCollaboration with Microsoft
10th Mar 20217:00 amRNSIXICO chosen for new Phase II AD study
2nd Mar 20217:00 amRNSIXICO selected by Cyclerion for a new AD study
1st Mar 20215:25 pmRNSExercise of Options; PDMR Dealing

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.